Paeoniflorin ameliorates glycemic variability-induced oxidative stress and platelet activation in HUVECs and DM rats

Huang, Ye; Wang, Jingshang; Yang, Lin; Long, Yunfei; Zhang, Lei; Zhang, Yanhong; Song, Ye-Wen; Li, Dandan; Yang, Zhixu

doi:10.1039/d0ra02036b

Cited by 6 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lidocaine and gentamicin were administered once daily for 3 d. Seventeen days later, the ovariectomized mice were randomly divided into three groups: control, PF 1 mg/kg, and PF 10 mg/kg, and then ear-punched to distinguish individual mice. A dose of PF was decided by referring to current research focused on the treatment of T2D with PF [ [20] , [21] , [22] ]. Subcutaneous injections of the sample were started on the mice once daily for 19 d.…”

Section: Methodsmentioning

confidence: 99%

Paeoniflorin, a constituent of Kami-shoyo-san, suppresses blood glucose levels in postmenopausal diabetic mice by promoting the secretion of estradiol from adipocytes

Kobayashi

Tang

Sasaki

2022

Biochemistry and Biophysics Reports

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Paeoniflorin, a constituent of Kami-shoyo-san, suppresses blood glucose levels in postmenopausal diabetic mice by promoting the secretion of estradiol from adipocytes

Kobayashi

Tang

Sasaki

2022

Biochemistry and Biophysics Reports

View full text Add to dashboard Cite

“…Basili et al [105] found that acute glucose fluctuations strongly correlated with urinary excretion of 8-iso-PGF2α, but no relationship was observed when urinary 8-iso-PGF2α excretion rates were plotted against main markers of sustained hyperglycemia (HbA1c and mean daily glucose concentrations). In our previous study, we explored platelet aggregation in HUVECs exposed to different GV media and healthy platelets and found that endothelial cells intermittently incubated with high glucose showed a more relevant increase in maximum platelet aggregation rate than the increase observed in the stable high-glucose condition [106].…”

Section: Platelet Hyperactivation In Gv-induced Dmassociated Complica...mentioning

confidence: 99%

Endothelial Dysfunction and Platelet Hyperactivation in Diabetic Complications Induced by Glycemic Variability

et al. 2022

Self Cite

View full text Add to dashboard Cite

The development and progression of the complications of chronic diabetes mellitus are attributed not only to increased blood glucose levels but also to glycemic variability. Therefore, a deeper understanding of the role of glycemic variability in the development of diabetic complications may provide more insight into targeted clinical treatment strategies in the future. Previously, the mechanisms implicated in glycemic variability-induced diabetic complications have been comprehensively discussed. However, endothelial dysfunction and platelet hyperactivation, which are two newly recognized critical pathogenic factors, have not been fully elucidated yet. In this review, we first evaluate the assessment of glycemic variability and then summarise the roles of endothelial dysfunction and platelet hyperactivation in glycemic variability-induced complications of diabetes, highlighting the molecular mechanisms involved and their interconnections.

show abstract

“…Mechanistically, PF can regulate the function of immune cells and endothelial cells (ECS), reduce the production of inflammatory mediators, and restore abnormal signal transduction [9]. PF has shown notable efficacy in treating rheumatoid arthritis, psoriasis, systemic lupus erythematosus, and diabetes [10][11][12][13].Importantly, PF has been reported to inhibit high glucose-induced macrophage activation and renal inflammation [14], ameliorate glycemic variability-induced oxidative stress [15], and improve the renal biochemical and pathological damage [16]. Although the existing evidence shows that PF has a therapeutic effect on DN, its potential mechanism of action has not been fully clarified.…”

Section: Introductionmentioning

confidence: 99%

Protective effect of paeoniflorin in diabetic nephropathy: A preclinical systematic review revealing the mechanism of action

Zhang,

Pang,

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Background Paeoniflorin (PF), the main active glucoside of Paeonia Lactiflora, has many pharmacological activities, such as inhibition of vasodilation, hypoglycemia, and immunomodulation. Although the current evidence has suggested the therapeutic effects of PF on diabetic nephropathy (DN), its potential mechanism of action is still unclear. Purpose A systematic review and meta-analysis of the existing literature on paeoniflorin treatment in DN animal models was performed to evaluate the efficacy and mechanism of PF in DN animal models. Methods The risk of bias in each study was judged using the CAMARADES 10-item quality checklist with the number of criteria met varying from 4 / 10 to 7 / 10, with an average of 5.44. From inception to July 2022, We searched eight databases. We used the Cochrane Collaboration’s 10-item checklist and RevMan 5.3 software to assess the risk of bias and analyze the data. Three-dimensional dose/time-effect analyses were conducted to examine the dosage/time-response relations between PF and DN. Results Nine animal studies were systematically reviewed to evaluate the effectiveness of PF in improving animal models of DN. Meta-analysis data and intergroup comparisons indicated that PF slowed the index of mesangial expansion and tubulointerstitial injury, 24-h urinary protein excretion rate, expression of anti-inflammatory mediators (mRNA of MCP-1, TNF-α, iNOS, and IL-1 β), and expression of immune downstream factors (P-IRAK1, TIRF, P-IRF3, MyD88, and NF-κBp-p65). Furthermore, modeling methods, animal species, treatment duration, thickness of tissue sections during the experiment, and experimental procedures were subjected to subgroup analyses. Conclusion The present study demonstrated that the reno-protective effects of PF were associated with its inhibition on macrophage infiltration, reduction of inflammatory mediators, and immunomodulatory effects. In conclusion, PF can effectively slow down the progression of DN and hold promise as a protective drug for the treatment of DN. Due to the low bioavailability of PF, further studies on renal histology in animals are urgently needed. We therefore recommend an active exploration of the dose and therapeutic time frame of PF in the clinic and in animals. Moreover, it is suggested to actively explore methods to improve the bioavailability of PF to expand the application of PF in the clinic.

show abstract

Paeoniflorin ameliorates glycemic variability-induced oxidative stress and platelet activation in HUVECs and DM rats

Abstract: Glycemic variability (GV) plays an important role in the pathogenesis of vascular complications associated with diabetes mellitus (DM).

Cited by 6 publications

References 41 publications

Paeoniflorin, a constituent of Kami-shoyo-san, suppresses blood glucose levels in postmenopausal diabetic mice by promoting the secretion of estradiol from adipocytes

Paeoniflorin, a constituent of Kami-shoyo-san, suppresses blood glucose levels in postmenopausal diabetic mice by promoting the secretion of estradiol from adipocytes

Endothelial Dysfunction and Platelet Hyperactivation in Diabetic Complications Induced by Glycemic Variability

Protective effect of paeoniflorin in diabetic nephropathy: A preclinical systematic review revealing the mechanism of action

Contact Info

Product

Resources

About